What is HC Wainwright’s Forecast for Omeros FY2029 Earnings?

Omeros Corporation (NASDAQ:OMER) – Research analysts at HC Wainwright reduced their FY2029 earnings per share (EPS) estimates for Omeros in a report released on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings per share of $3.59 for the year, down from their prior estimate of $3.95. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Omeros’ FY2030 earnings at $4.62 EPS.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million.

Several other research analysts have also issued reports on the stock. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen downgraded Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, June 7th. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.00.

Omeros Price Performance

Shares of OMER opened at $17.35 on Friday. Omeros has a 1-year low of $3.94 and a 1-year high of $18.14. The company has a market capitalization of $1.26 billion, a P/E ratio of 13.55 and a beta of 2.54. The firm’s 50 day simple moving average is $10.74 and its 200 day simple moving average is $11.50.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. Compass Financial Management LLC bought a new position in shares of Omeros during the second quarter valued at about $312,000. BlackRock Inc. purchased a new position in Omeros during the 2nd quarter valued at about $57,484,000. Deutsche Bank AG purchased a new position in Omeros during the 2nd quarter valued at about $714,000. Bank of New York Mellon Corp bought a new position in Omeros during the 2nd quarter valued at approximately $1,864,000. Finally, Pictet Asset Management Holding SA purchased a new stake in Omeros in the 2nd quarter worth approximately $171,000. 48.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the sale, the director owned 35,067 shares in the company, valued at approximately $407,127.87. The trade was a 17.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by company insiders.

Trending Headlines about Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros reported second-quarter EPS of $0.02, sharply ahead of the $0.27-per-share loss analysts expected and an improvement from a $0.53 loss a year earlier. Revenue of $28.53 million also more than doubled the $12.69 million consensus estimate. Omeros earnings results
• Positive Sentiment: Management’s earnings update emphasized accelerating YARTEMLEA sales, a leaner balance sheet through debt reduction and planned share buybacks. These developments support the case for stronger future cash flow and shareholder returns. Omeros sales momentum and balance sheet update
• Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $33 price target, citing strong YARTEMLEA adoption and reduced C5 competition as potential catalysts. Omeros Buy rating and price target
• Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment may strengthen governance and investor engagement, although its direct financial impact is unclear. Omeros appoints Joseph Schocken
• Neutral Sentiment: Trading in Omeros call options rose 235% above typical volume, signaling increased bullish speculation but also potentially greater short-term volatility.
• Negative Sentiment: HC Wainwright reduced its long-term EPS estimates to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. The analyst remains bullish, but the revisions indicate somewhat lower projected earnings power.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.